{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Part 1 only","groups":[{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy","id":"OG000","title":"Part 1: Cemiplimab + Chemotherapy"},{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab","id":"OG001","title":"Part 1: Cemiplimab+AbbrevChemo+Ipilimumab"},{"description":"Participants received platinum-based doublet chemotherapy","id":"OG002","title":"Part 1: Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only the first 10 participants enrolled in the Cemiplimab+AbbrevChemo+ipilimumab arm were DLT evaluable, defined as the participants who completed the DLT observation period and those participants who discontinued early due to the development of a DLT. The participants were analyzed as treated.","reportingStatus":"POSTED","timeFrame":"28 days","title":"Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)","type":"SECONDARY","unitOfMeasure":"Participants"}